Abstract
The evolving dynamics of coronavirus disease 2019 (COVID-19) and the increasing infection numbers require diagnostic tools to identify patients at high risk for a severe disease course. Here we evaluate clinical and imaging parameters for estimating the need of intensive care unit (ICU) treatment. We collected clinical, laboratory and imaging data from 65 patients with confirmed COVID-19 infection based on PCR testing. Two radiologists evaluated the severity of findings in computed tomography (CT) images on a scale from 1 (no characteristic signs of COVID-19) to 5 (confluent ground glass opacities in over 50% of the lung parenchyma). The volume of affected lung was quantified using commercially available software. Machine learning modelling was performed to estimate the risk for ICU treatment. Patients with a severe course of COVID-19 had significantly increased IL-6, CRP and leukocyte counts and significantly decreased lymphocyte counts. The radiological severity grading was significantly increased in ICU patients. Multivariate random forest modelling showed a mean ± standard deviation sensitivity, specificity and accuracy of 0.72 ± 0.1, 0.86 ± 0.16 and 0.80 ± 0.1 and a ROC-AUC of 0.79 ± 0.1.
The need for ICU treatment is independently associated with affected lung volume, radiological severity score, CRP and IL-6.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no external funding was received
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authors’ email addresses Egon Burian: egon.burian{at}tum.de
Friederike Jungmann: friederike.jungmann{at}tum.de
Georgios Kaissis: g.kaissis{at}tum.de
Fabian Lohöfer: fabian.lohoefer{at}tum.de
Christoph D. Spinner: christoph.spinner{at}tum.de
Gerhard Schneider: gerhard.schneider{at}tum.de
Fabian Geisler: fabian.geisler{at}tum.de
Michael Dommasch: michael.dommasch{at}tum.de
Matthias Treiber: matthias.treiber{at}mri.tum.de
Tobias Lahmer: tobias.lahmer{at}mri.tum.de
Wolfgang Huber: wolfgang.huber{at}tum.de
Ulrike Protzer: protzer{at}tum.de
Roland M. Schmid: direktion.med2{at}mri.tum.de
Markus Schwaiger: markus.schwaiger{at}tum.de
Marcus R. Makowski: marcus.makowski{at}tum.de
Rickmer F. Braren: rbraren{at}tum.de
Data Availability
All data is available in the manuscript or supplementary section.
Abbreviations
- AUC
- :area under the curve
- COVID-19
- :corona disease 2019
- HU
- :Hounsfield units
- ICU
- :intensive care unit
- MDCT
- :multi-detector computed tomography
- PACS
- :picture archiving and communication system
- ROC
- :receiver operating characteristics
- ROI
- :region of interest
- SARS-CoV-2
- :Severe acute respiratory syndrome coronavirus 2
- SD
- :standard deviation
